Want to see HK:9955 full AI Analyst Report?
9955 Stock Chart & Stats
HK$1.00
HK$0.03(2.52%)
At close: 4:00 PM EST
HK$1.00
HK$0.03(2.52%)
Day’s Range― - ―
52-Week RangeHK$0.46 - HK$1.55
Previous CloseN/A
Volume146.50K
Average Volume (3M)1.09M
Market Cap
HK$328.15M
Enterprise ValueHK$83.79
Total Cash (Recent Filing)HK$410.55M
Total Debt (Recent Filing)HK$288.63M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Mar 25, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding645,718,800
10 Day Avg. Volume899,970
30 Day Avg. Volume1,090,236
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.00
Price to Sales (P/S)0.34
P/FCF Ratio-8.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.11
Revenue Forecast (FY)HK$7.73B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StabilizationPositive equity and moderate leverage provide a more stable financial base than in 2020–2021. This improves resilience and financing flexibility, although persistent losses could erode that improvement over time.
Improved Operating Cash FlowThe return to positive operating cash flow indicates better cash conversion from core operations and may support business continuity. However, the improvement needs to persist before it can be considered a durable funding advantage.
Gross Margin ImprovementA substantially higher gross margin suggests improved product mix, procurement, or pricing economics. If sustained across the omnichannel pharmacy network, it could strengthen unit economics and create a path toward eventual profitability.
Bears Say
Sharp Revenue ContractionThe sharp contraction signals weakening scale, customer demand, or channel productivity across the healthcare retail platform. Sustained revenue pressure would reduce operating leverage and make it harder to absorb fixed store and corporate costs.
Persistent Large Net LossesDeep net losses show that improved product-level economics have not translated into sustainable company-wide profitability. Continued losses can consume equity, constrain investment capacity, and increase dependence on external financing.
Negative Free Cash FlowNegative free cash flow means the business is still not self-funding after investment and working-capital requirements. Until cash generation becomes consistently positive, expansion and ongoing operations may place pressure on liquidity and capital resources.
ClouDr Group Limited News
9955 FAQ
What was ClouDr Group Limited’s price range in the past 12 months?
ClouDr Group Limited lowest stock price was HK$0.46 and its highest was HK$1.55 in the past 12 months.
What is ClouDr Group Limited’s market cap?
ClouDr Group Limited’s market cap is HK$328.15M.
When is ClouDr Group Limited’s upcoming earnings report date?
ClouDr Group Limited’s upcoming earnings report date is Mar 25, 2027 which is in 208 days.
How were ClouDr Group Limited’s earnings last quarter?
ClouDr Group Limited released its earnings results on Aug 27, 2026. The company reported -HK$0.054 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is ClouDr Group Limited overvalued?
According to Wall Street analysts ClouDr Group Limited’s price is currently Overvalued.
Does ClouDr Group Limited pay dividends?
ClouDr Group Limited does not currently pay dividends.
What is ClouDr Group Limited’s EPS estimate?
ClouDr Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ClouDr Group Limited have?
ClouDr Group Limited has 645,718,800 shares outstanding.
What happened to ClouDr Group Limited’s price movement after its last earnings report?
ClouDr Group Limited reported an EPS of -HK$0.054 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.03%.
Which hedge fund is a major shareholder of ClouDr Group Limited?
Currently, no hedge funds are holding shares in HK:9955
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ClouDr Group Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-38.03%
Trailing 12-Months
Company Description
ClouDr Group Limited
ClouDr Group Limited operates as an investment holding company, providing a diverse range of services within the healthcare sector. The firm supplies hospitals and pharmacies with crucial medical products, including devices like blood glucose meters and vital sign monitors, glucose testing strips, and both over-the-counter and prescription drugs. In addition to physical goods, ClouDr delivers software-as-a-service (SaaS) platforms tailored for healthcare facilities and pharmacies, while also offering digital marketing solutions to pharmaceutical companies. Furthermore, the company facilitates the management of chronic conditions through real-time online consultations, digital health monitoring, and remote prescription and ordering services. Established in 2014, ClouDr Group Limited maintains its primary corporate office in Hangzhou, China.
Technical Analysis
China Health Group
―
Sinopharm Group Co
―
IVD Medical Holding Limited
―
Medlive Technology Co., Ltd.
―
Charmacy Pharmaceutical Co., Ltd. Class H
―